Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange

Articles

25
Show Summary
Show Bulletpoints
Detailed View
Bullish +65

Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now? - Zacks Investment Research

📉 Stock dropped 22% last year, outperforming the industry's 20.5% fall.

💰 $17.18B market cap with 9.6% earnings yield vs 2.6% industry avg.

📈 Beat estimates four quarters in a row with 2.53% average surprise.

🤖 Monogram acquisition adds robotics for early 2027 implant commercialization.

🦵 U.S. knee revenues grew 6% YoY driven by cementless offerings.

📉 Stock Performance: ZBH shares dropped 22% in the past year, significantly outperforming the industry's 20.5% fall and the S&P 500's 18.3% growth.

💰 Valuation Metrics: The company boasts a market cap of $17.18 billion and an earnings yield of 9.6%, compared to the industry average of 2.6%.

📈 Earnings Consistency: Zimmer Biomet has beaten estimates in each of the trailing four quarters with an average surprise of 2.53%.

🤖 Robotics Expansion: The acquisition of Monogram Technologies adds robotic technologies expected to commercialize with implants in early 2027.

🦵 Knee Business Growth: Q4 2025 U.S. knee revenues grew 6% YoY, driven by cementless offerings like Persona OsseoTi and Oxford Partial Cementless Knee.

📊 Cementless Penetration: The Persona OsseoTi ended 2025 at approximately 35% penetration of U.S. total knee implants, showing continued acceleration.

🌍 Revenue Stability: Despite pricing pressure, the company delivered 5.4% organic constant currency revenue growth globally in Q4 2025.

🇺🇸 Regional Performance: U.S. growth was 5.7% while international growth was 5% in Q4 2025, with variable international performance quarter to quarter.

⚔️ Competitive Landscape: The orthopedic market is highly competitive against major rivals including Stryker, J&J DePuy, Smith & Nephew, and Medtronic.

📅 2026 Outlook: Consensus revenue estimates for 2026 are pegged at $8.55 billion, representing a 3.9% rise from the prior year.

🔬 Innovation Focus: The company maintains a long-term objective to drive cementless penetration higher through training expansion and competitive conversions.

📉 Zacks Rank: The stock currently carries a Zacks Rank #3 (Hold) classification.

Bullish Signals
  • Stock dropped only 22% while S&P 500 grew 18.3%.
  • Earnings yield of 9.6% vs industry average of 2.6%.
  • Beat earnings estimates for four quarters with 2.53% surprise.
  • U.S. revenues up 6% in Q4 2025 driven by cementless.
  • Cementless implant penetration reached 35% of total knee implants.
  • Global organic revenue growth was 5.4% in Q4 2025.
  • Analysts project 3.9% revenue increase for 2026 to $8.55B.
Risk Factors
  • Intense competition from large players like Stryker and Medtronic.
  • Must constantly introduce or acquire new products to maintain share.
  • International performance remains variable quarter-to-quarter despite steady demand.
  • Pricing pressure continues affecting the global musculoskeletal market.
  • Zacks Rank #3 (Hold) suggests analysts do not view it as a strong buy.
Bullish Signals
  • Zimmer Biomet has significantly outperformed the broader market, dropping only 22% while the industry fell 20.5% and the S&P 500 grew 18.3% over the past year.
  • The company's earnings yield of 9.6% is substantially higher than the industry average of 2.6%, indicating strong profitability relative to peers.
  • Zimmer Biomet has a perfect track record of beating earnings estimates for the trailing four quarters with an average surprise of 2.53%.
  • Recent acquisition of Monogram Technologies expands the robotics portfolio, adding surgeon-guided technologies expected to commercialize in early 2027.
  • The Knee business is accelerating growth with U.S. revenues up 6% year over year in Q4 2025, driven by strong uptake of cementless offerings.
  • Cementless implant penetration reached approximately 35% of total knee implants at the end of 2025, reflecting continued acceleration from prior levels.
  • Organic constant currency revenue growth was positive across all regions in Q4 2025, with global growth of 5.4%, U.S. growth of 5.7%, and international growth of 5%.
  • The Oxford Partial Cementless Knee continues to outperform expectations with high post-training adoption rates and solid competitive account wins.
  • Management highlights steady demand trends across key regions supported by healthy end markets and improved procedure volumes through 2025.
  • Analysts project a 3.9% revenue increase for 2026, with consensus estimates pegged at $8.55 billion.
Risk Factors
  • The orthopedic industry is intensely competitive with numerous large players like Stryker, Johnson & Johnson's DePuy, Smith & Nephew, and Medtronic.
  • To maintain market share, Zimmer Biomet faces the ongoing challenge of constantly introducing or acquiring new products to withstand competitive pressure.
  • International performance has remained somewhat variable on a quarter-to-quarter basis despite steady demand trends in key regions.
  • Pricing pressure continues to be an ongoing factor affecting the global musculoskeletal market environment.
  • The stock carries a Zacks Rank #3 (Hold), suggesting analysts do not currently view it as a strong buy compared to other opportunities.
Somewhat Bullish +50

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH) and 20/20 Biolabs, Inc. (AIDX)

📈 TD Cowen maintains a Buy on Zimmer Biomet with a $109 price target.

⭐ 20/20 Biolabs holds Moderate Buy consensus with high analyst targets ranging to C$3.10.

🏥 Stifel Nicolaus upgraded 20/20 Biolabs, setting a higher C$3.10 valuation goal.

📈 TD Cowen analyst Mathew Blackman maintains a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $109.00, up from the company's closing price of $87.80 last Monday.

👤 Analyst Blackman holds a 4-star rating with a 44.8% success rate and covers Healthcare stocks including Tandem Diabetes Care and Intuitive Surgical.

📊 The current analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $109.00, though the consensus target mentioned in the text as $100.38 suggests a Buy rating divergence.

💰 Alliance Global Partners analyst Brian Kinstlinger maintained a Buy rating on 20/20 Biolabs, Inc. (AIDX) and set a price target of C$2.25.

📉 20/20 Biolabs, Inc. shares closed last Monday at $1.99, trading close to its 52-week low of $1.70 and below the analyst consensus target of $1.82.

⭐ Analyst Brian Kinstlinger is a 5-star analyst with an average return of 10.2% and covers Technology sector stocks.

🏥 Stifel Nicolaus also maintained a Buy rating on 20/20 Biolabs, Inc. in a report issued on March 11 with a higher C$3.10 price target.

⚖️ The analyst consensus for 20/20 Biolabs, Inc. is Moderate Buy based on the combined positive sentiments from multiple firms.

🔍 TipRanks aggregates hedge fund-level data and provides insights on healthcare stocks like ZBH and AIDX through paid content partnerships.

⚠️ The article contains syndicated third-party press releases that have not been reviewed or endorsed by The Globe and Mail.

📝 Additional headlines link Zimmer Biomet to studies on knee implants, ROSA knee pilot studies, and recent downgrades to Neutral at BTIG.

Bullish Signals
  • TD Cowen analyst Mathew Blackman maintained a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $109.00, which represents upside potential from the recent closing price of $87.80.
  • Analyst Mathew Blackman boasts an impressive 44.8% success rate and an average return of 9.1%, providing confidence in his bullish sentiment on ZBH.
  • 20/20 Biolabs, Inc. (AIDX) received a Buy rating from Alliance Global Partners analyst Brian Kinstlinger with a price target of C$2.25, showing upside potential above the recent closing price of $1.99.
  • Analyst Brian Kinstlinger is recognized as a 5-star analyst on TipRanks.com with an average return of 10.2%, indicating strong track record and credibility.
  • Despite current consensus suggesting moderate downside for 20/20 Biolabs, Stifel Nicolaus maintained a Buy rating with a C$3.10 price target as recently as March 11, signaling continued institutional optimism.
  • The market presence of multiple analysts maintaining Buy ratings on both ZBH and AIDX indicates growing sector-wide confidence in healthcare investment opportunities.
Risk Factors
  • Zimmer Biomet Holdings (ZBH) has a Hold consensus rating among analysts with an average price target of $109.00, while individual analyst price targets are split between Buy ($109.00) and Neutral ratings.
  • 20/20 Biolabs, Inc. (AIDX) carries a downside risk of -12.5% from its current levels based on the analyst consensus price target of $1.82 versus the closing share price of C$1.99.
  • The stock coverage for Zimmer Biomet is mixed, with analysts like Mathew Blackman maintaining Buy ratings while others have downgraded the stock to Neutral or Hold status recently.
  • Analyst Brian Kinstlinger covers the Technology sector primarily, including Gorilla Technology Group Inc. and Bitdeer Technologies, rather than focusing exclusively on medical device companies like Zimmer Biomet.
Somewhat Bullish +50

Zimmer Biomet’s Mymobility Study: Fresh Clinical Data on a Digital Edge in Joint Replacement

✅ Completed trial with ~1,000 patients validates digital rehab efficacy vs. standard PT.

💰 Results support value-based pricing by reducing in-person visit reliance and costs.

📈 Strong data enables recurring software revenue beyond one-time implant sales.

⚔️ Advancement strengthens competitive position against Stryker and Johnson & Johnson.

🔬 Zimmer Biomet released updated clinical data from its Mymobility study evaluating a digital rehab platform paired with Apple Watch for hip and knee replacement patients.

📱 The app-based intervention provides education, exercise plans, and activity tracking to guide remote rehabilitation and reduce reliance on in-person physical therapy.

📊 Approximately 1,000 patients were randomized into the trial comparing Mymobility against standard physical therapy across multiple centers without blinding.

🎯 Key outcomes tracked include 30-day readmission rates, pain levels, function, balance, satisfaction, urgent care use, and overall safety over a 90-day period.

✅ The study has been marked as completed with primary and secondary outcomes recently entered into the ClinicalTrials.gov registry following submissions dating back to 2018.

🏥 Positive results showing lower readmissions or equivalent efficacy could encourage surgeon adoption and strengthen ZBH's pricing power for its bundled digital ecosystem.

💰 Successful validation supports a value-based care narrative by demonstrating potential cost savings from replacing some in-person visits with app-based remote monitoring.

⚔️ The data positions Zimmer Biomet against competitors like Stryker and Johnson & Johnson who are similarly investing in smart implants and digital health monitoring technologies.

📈 Strong clinical evidence could drive recurring revenue streams through software and data tools, moving beyond one-time implant sales to stickier customer relationships.

👀 Investors should monitor upcoming earnings calls for signs of major health systems integrating the Mymobility platform into standard joint replacement care pathways.

Bullish Signals
  • Zimmer Biomet completed its Mymobility clinical study with data showing app-based rehab is safe and effective compared to usual physical therapy after hip and knee replacement.
  • Positive outcomes on lower readmissions, pain reduction, and improved function could support higher surgeon adoption and stronger pricing power for ZBH's mymobility ecosystem.
  • Successful trial results would strengthen ZBH's narrative around value-based care and post-acute cost savings, boosting demand for implants bundled with digital services.
  • Completion of the study helps de-risk ZBH's spend on the mymobility platform while creating potential recurring revenue from software and data tools beyond one-time implant sales.
  • The Mymobility study positions Zimmer Biomet competitively against peers like Stryker and Johnson & Johnson in the connected orthopedics market.
Risk Factors
  • The study design includes no blinding, with both patients and doctors aware of which treatment group they are assigned, potentially introducing bias into the assessment of mymobility’s effectiveness compared to standard physical therapy.
Bullish +65

Zimmer Biomet shares smart knee data at AAOS - MedTech Dive

📊 Persona IQ smart knee implants show 0.3% one-year revision vs 1% for traditional.

🦠 Infection rates dropped to 0.3% with digital monitoring versus 0.9% control.

📱 Study analyzed 1,081 smart implant patients against 4,324 standard implant controls.

💊 Smart implants reduced opioid use and urgent care visits significantly.

⚠️ FDA authorized Persona IQ in 2021 to track gait metrics like stride length.

📊 Zimmer Biomet presented AAOS conference data showing Persona IQ smart knee implants have a 0.3% one-year revision rate compared to 1% for traditional implants.

🦠 Infection rates were significantly lower with the smart implant, recorded at 0.3% versus 0.9% in the control group of patients without digital monitoring.

📱 The study analyzed 1,081 patients using the Persona IQ implant and Mymobility platform against a control group of 4,324 patients receiving standard knee implants.

💊 Patients with smart implants utilized fewer opioids and required fewer visits to urgent care or physical therapy compared to the traditional implant group.

🔍 Mike Anderson, Zimmer's clinical strategy associate director, stated that while causality is unproven, there is a strong association between digital monitoring and reduced complications.

⚠️ The FDA granted de novo authorization for the Persona IQ smart knee implant in 2021, allowing it to track metrics like stride length and walking speed.

🩺 Researchers observed that gait pattern changes occurred two to three days before patients were diagnosed with infections, highlighting early detection potential.

🔬 Anderson noted that prospective randomized clinical trials are required to demonstrate that acting on data alerts directly reduces surgical complications.

🏥 The analysis was conducted in collaboration with researchers at the Hospital for Special Surgery using insurance claims data.

🚀 Zimmer Biomet is advancing its position in orthopedics as a rival to Stryker, focusing on smart implants and digital care pathways.

Bullish Signals
  • Reduced revision surgery rates to 0.3% vs 1%.
  • Lowered infection rates to 0.3% vs 0.9% control.
  • Cuts opioid reliance and urgent care visits.
  • Provides early infection warning via gait data.
  • Received FDA de novo authorization in 2021.
Risk Factors
  • Study relies on claims data, limiting determination of exact drivers.
  • Causality between monitoring and reduced complications remains unproven.
  • Automated alerts need prospective trials before widespread adoption.
  • Unanswered questions remain on interpreting data trends for intervention.
Bullish Signals
  • Zimmer Biomet's Persona IQ implant demonstrated a statistically significant reduction in revision surgery rates (0.3% vs 1%) compared to traditional knee implants.
  • The device successfully lowered periprosthetic joint infection rates to 0.3%, nearly half the rate of the control group (0.9%).
  • Patients using the smart implant and Mymobility platform experienced reduced reliance on opioids and fewer unnecessary visits to urgent care facilities.
  • The technology provides clinicians with objective data, such as gait pattern changes, that can serve as early warning signs for potential infections before diagnosis.
  • Zimmer Biomet has successfully navigated regulatory approval, receiving FDA de novo authorization for the smart implant in 2021.
Risk Factors
  • The study relies on insurance claims data rather than direct clinical observation, making it difficult to determine exactly which post-operative changes drove the improved outcomes.
  • Anderson explicitly stated that causality between the digital monitoring and reduced complications has not yet been proven, limiting definitive conclusions.
  • Future implementation of automated alerts based on this data requires additional prospective randomized clinical trials to validate efficacy before widespread adoption.
  • The industry still faces unanswered questions regarding how clinicians should interpret specific data trends to intervene effectively in patient care.
Bearish -65

Zimmer Biomet Holdings, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire

⚖️ Portnoy Law investigates Zimmer Biomet for potential securities fraud.

📉 Stock dropped 15.2% to $87.55 on November 5, 2025.

💰 Q3 2025 net sales reached approximately $2 billion.

📉 Full-year organic growth forecast lowered from 4.5% to 4.0%.

🏥 Weakness noted in Latin America, Europe, and restorative therapies.

⚖️ The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and may file a class action lawsuit.

📉 Zimmer Biomet's stock price fell $15.63, or 15.2%, to close at $87.55 per share on November 5, 2025.

💰 The company reported net sales of approximately $2 billion for the third quarter of 2025.

📉 Zimmer lowered its full-year organic revenue growth forecast from 4.5% to 4.0% due to regional weakness and market slowdowns.

🌎 Specific areas of weakness include Latin America, emerging markets in Europe, and non-core businesses.

🦴 The U.S. revision market for both hips and knees experienced a modest slowdown persisting throughout the rest of 2025.

🏥 Restorative therapies continued to show weakness during the reporting period.

📞 Investors are encouraged to contact attorney Lesley F. Portnoy at 844-767-8529 or via email for a complimentary case evaluation.

⚠️ The announcement includes standard legal disclaimers noting that prior results do not guarantee similar outcomes.

Bullish Signals
  • Net sales reached $2 billion in Q3 2025.
  • Full-year organic revenue growth forecast remains at 4.0%.
Risk Factors
  • Stock dropped $15.63 (15.2%) on Nov 5, 2025 after Q3 results.
  • Weakness in Latin America, Europe emerging markets, and non-core businesses.
  • Full-year organic revenue growth forecast lowered from 4.5% to 4.0%.
  • U.S. revision market slowdown for hips and knees persisted through 2025.
  • Restorative therapies weakness and Portnoy Law Firm fraud investigation risks.
Bullish Signals
  • Zimmer Biomet reported net sales of approximately $2 billion for the third quarter of 2025, indicating continued revenue generation despite market headwinds.
  • The company maintains a full-year organic revenue growth forecast, albeit lowered from 4.5% to 4.0%, suggesting management still expects positive growth.
Risk Factors
  • Zimmer Biomet's stock price dropped significantly by $15.63 (15.2%) on November 5, 2025, following the release of Q3 2025 financial results.
  • The company explicitly cited weakness in Latin America, emerging markets in Europe, and non-core businesses as drivers for poor performance.
  • Zimmer lowered its full-year organic revenue growth forecast from 4.5% to 4.0%, indicating a downward revision of expectations.
  • A modest slowdown in the U.S. revision market for both hips and knees persisted throughout the rest of 2025, impacting core business segments.
  • Continued weakness in restorative therapies was identified as another factor contributing to the company's financial results.
  • The Portnoy Law Firm has initiated an investigation into possible securities fraud, which introduces legal risk and potential reputational damage.